Fresenius Medical Care Publishes Study Showing 28% Lower Mortality Risk with Hemodiafiltration
FMS sits 16% above its 52-week low of $20.02.
Summary
Fresenius Medical Care announced publication of a multinational real-world evidence study in JASN showing hemodiafiltration was associated with a 28% lower relative risk of all-cause mortality versus conventional hemodialysis, with a 33% reduction for high-volume HDF.
Key Events · Product Development and Regulatory · FMS
-
JASN Publication Shows 28% Mortality Reduction
A multinational real-world evidence study published in the Journal of the American Society of Nephrology found hemodiafiltration (HDF) was associated with a 28% lower relative risk of all-cause mortality compared with high-flux hemodialysis.
-
High-Volume HDF Shows 33% Mortality Benefit
Patients receiving sustained HDF with convection volumes above 23 liters per session had a 33% lower relative risk of death, highlighting the importance of consistently delivering high convection volumes.
-
Study Design and Scale
The target trial emulation analyzed 19,539 adult dialysis patients across eight European countries treated between 2014 and 2019, with a median follow-up of 16 months.
-
Supports U.S. HVHDF Expansion Strategy
The publication reinforces the company's BEACON-US initiative and its push to expand access to high-volume hemodiafiltration in the United States, where the therapy is not yet standard of care.
Analysis · FMS · Industrial Applications And Services
The JASN publication delivers the strongest real-world evidence to date that high-volume hemodiafiltration (HVHDF) cuts all-cause mortality by 28% versus conventional hemodialysis, and by 33% for patients with convection volumes above 23 liters per session. This directly bolsters the company's strategic drive to expand HVHDF access in the United States, where it is not yet standard of care. With a target trial emulation design and nearly 20,000 patients across eight European countries, the findings carry substantial credibility, potentially accelerating adoption of Fresenius Medical Care's HDF-capable dialysis machines and consumables.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FMS was trading at $23.27 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $20.02 to $27.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.